CD248蛋白在肺动脉高压中的表达及其临床意义

董永洁; 黄玮

doi:10.16016/j.2097-0927.202110043

您当前的位置：

首页 >

文章列表页 >

CD248蛋白在肺动脉高压中的表达及其临床意义

临床医学 | 更新时间：2026-01-09

- CD248蛋白在肺动脉高压中的表达及其临床意义
- Expression of CD248 in pulmonary arterial hypertension and its clinical significance
- 陆军军医大学学报 2022年44卷第12期页码：1266-1271
- 作者机构：
  
  400016 重庆，重庆医科大学附属第一医院心血管内科
- 作者简介：
  
  [黄玮, E-mail: weihuangcq@gmail.comHUANG Wei, E-mail: weihuangcq@gmail.com
- 基金信息：
  
  重庆市卫生计生委医学科研项目(2016HBRC001)
- DOI：10.16016/j.2097-0927.202110043
  中图分类号： R341;R446.112;R543.2
- 收稿：2021-10-11，
  
  修回：2022-01-18，
  
  纸质出版：2022-06-30
- 稿件说明：
移动端阅览
董永洁, 黄玮. CD248蛋白在肺动脉高压中的表达及其临床意义[J]. 陆军军医大学学报, 2022,44(12):1266-1271.

Yongjie DONG, Wei HUANG. Expression of CD248 in pulmonary arterial hypertension and its clinical significance[J]. Journal of Army Medical University, 2022, 44(12): 1266-1271.
董永洁, 黄玮. CD248蛋白在肺动脉高压中的表达及其临床意义[J]. 陆军军医大学学报, 2022,44(12):1266-1271. DOI： 10.16016/j.2097-0927.202110043.

Yongjie DONG, Wei HUANG. Expression of CD248 in pulmonary arterial hypertension and its clinical significance[J]. Journal of Army Medical University, 2022, 44(12): 1266-1271. DOI： 10.16016/j.2097-0927.202110043.

摘要

目的

研究肺动脉高压(pulmonary arterial hypertension

PAH)患者的血浆CD248水平及其临床意义。

方法

共纳入本科于2016年3月至2019年6月经右心导管检查明确诊断的PAH患者30例和健康对照者12例，其中PAH患者包括14例特发性肺动脉高压(idiopathic pulmonary arterial hypertension

IPAH)患者和16例慢性肺栓塞型肺动脉高压(chronic thromboembolic pulmonary hypertension

CTEPH)患者。使用ELISA检测健康对照者和PAH患者血浆中CD248蛋白水平。使用野百合碱(monocrotaline

MCT)诱导Sprague Dawley大鼠PAH，通过ELISA检测大鼠血浆中CD248蛋白表达。进一步通过体外实验予以肿瘤坏死因子α(tumor necrosis factor-α

TNF-α) 或血小板源生长因子BB(platelet-derived growth factor-BB

PDGF-BB)干预大鼠肺动脉平滑肌细胞(pulmonary artery smooth muscle cells

PASMCs)，检测CD248 mRNA的表达。

结果

PAH患者血浆中的CD248水平明显低于健康对照者(

0.01)。受试者工作特征曲线(receiver operating characteristic curve，ROC)下面积(area under the curve

AUC)为0.79(95%

: 0.64~0.94

0.01)。同样地，野百合碱处理组大鼠血浆中CD248蛋白水平均较对照组降低。血小板源生长因子BB干预后，PASMCs中CD248 mRNA的表达先上调后下调。

结论

CD248在PAH患者血浆中表达降低，其具有作为生物标记物用于辅助诊断PAH的潜力。

Abstract

Objective

Too investigate the plasma level of CD248 in patients with pulmonary arterial hypertension (PAH) and its clinical significance.

Methods

A total of 30 PAH patients

including 14 with idiopathic pulmonary arterial hypertension (IPAH) and 16 with chronic thromboembolic pulmonary hypertension (CTEPH) who were diagnosed by right heart catheterization in the our department from March 2016 to June 2019 were recruited

and 12 healthy individuals who taking physical examination during same period served as control group in this study. Plasma levels of CD248 protein in healthy controls and PAH patients were detected using ELISA. After monocrotaline (MCT) was used to induce PAH in SD rats

and the level of CD248 in rat plasma was also detected by ELISA. Then

in vitro

after rat pulmonary artery smooth muscle cells (PASMCs) were isolated and identified and then cultured to passages 5~7

they were treated with TNF-α or platelet-derived growth factor-BB (PDGF-BB)

and the mRNA expression of CD248 in the cells was measured with qPCR.

Results

The plasma level of CD248 was significantly lower in the PAH patients than the healthy controls (

0.01). Its area under the curve (AUC) of the receiver ope

rating characteristic (ROC) curve for PAH was 0.79 (95%

: 0.64~0.94

0.01). Similarly

the level of CD248 in the plasma of rats was lower in the MCT treatment group than the control group. After the intervention of PDGF-BB

the mRNA level of CD248 in PASMCs was first up-regulated and then down-regulated.

Conclusion

CD248 is lowly expressed in the plasma of PAH patients

and it has the potential to be used as a biomarker to assist in the diagnosis of PAH.

关键词

Keywords

references

MCLAUGHLIN V V. Looking to the future: a new decade of pulmonary arterial hypertension therapy[J]. Eur Respir Rev, 2011, 20(122): 262-269. DOI: 10.1183/09059180.00006411.

PEACOCK A J. National Pulmonary Hypertension Services of UK and Ireland. Treatment of pulmonary hypertension[J]. BMJ, 2003, 326(7394): 835-836. DOI: 10.1136/bmj.326.7394.835.

D'ALONZO G E, BARST R J, AYRES S M, et al . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry[J ] . Ann Intern Med, 1991, 115(5): 343-349. DOI: 10.7326/0003-4819-115-5-343.

KHAN K A, MCMURRAY J L, MOHAMMED F, et al . C-type lectin domain group 14 proteins in vascular biology, cancer and inflammation[J ] . FEBS J, 2019, 286(17): 3299-3332. DOI: 10.1111/febs.14985.

HASANOV Z, RUCKDESCHEL T, KÖNIG C, et al . Endosialin promotes atherosclerosis through phenotypic remodeling of vascular smooth muscle cells[J ] . Arterioscler Thromb Vasc Biol, 2017, 37(3): 495-505. DOI: 10.1161/ATVBAHA.116.308455.

SURESH BABU S, VALDEZ Y, XU A, et al . TGFβ-mediated suppression of CD248 in non-cancer cells via canonical Sm ad-dependent signaling pathways is uncoupled in cancer cells[J ] . BMC Cancer, 2014, 14: 113. DOI: 10.1186/1471-2407-14-113..

BARTIS D, CROWLEY L E, D'SOUZA V K, et al . Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis[J ] . BMC Pulm Med, 2016, 16(1): 51. DOI: 10.1186/s12890-016-0211-7.

PIETRZYKŁ, WDOWIAK P. Endosialin (TEM1) as a diagnostic, progression, and prognostic serum marker for patients with colorectal cancer-A preliminary study[J]. Cancer Control, 2020, 27(1): 1073274820903351. DOI: 10.1177/1073274820903351.

GUIGNABERT C, DORFMULLER P. Pathology and patho-biology of pulmonary hypertension[J]. Semin Respir Crit Care Med, 2013, 34(5): 551-559. DOI: 10.1055/s-0033-1356496.

BAROZZI C, GALLETTIM, TOMASI L, et al . A combined targeted and whole exome sequencing approach identified novel candidate genes involved in heritable pulmonary arterial hypertension[J ] . Sci Rep, 2019, 9(1): 753. DOI: 10.1038/s41598-018-37277-0.

XU T, SHAO L, WANG A M, et al . CD248 as a novel therapeutic target in pulmonary arterial hypertension[J ] . Clin Transl Med, 2020, 10(5): e175. DOI: 10.1002/ctm2.175.

TSAI C H, MA H P, LIN Y T, et al . Heart rhythm complexity impairment in patients with pulmonary hypertension[J ] . Sci Rep, 2019, 9(1): 10710. DOI: 10.1038/s41598-019-47144-1.

中华医学会心血管病学分会肺血管病学组, 中华心血管病杂志编辑委员会. 中国肺高血压诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(12): 933-964. DOI: 10.3760/cma.j.issn.0253-3758.2018.12.006.

Working Group on Pulmonary Vascular Diseases of Chinese Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Chinese guidelines forthe diagnosis and treatment of pulmonary hypertension 2018[J]. Chin J Cardiol, 2018, 46(12): 933-964. DOI: 10.3760/cma.j.issn.0253-3758.2018.12.006.

NOGUEIRA-FERREIRA R, VITORINO R, FERREIRA R, et al . Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: a network approach[J ] . Pulm Pharmacol Ther, 2015, 35: 8-16. DOI: 10.1016/j.pupt.2015.09.007.

DUMITRASCU R, KOEBRICH S, DONY E, et al . Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury[J ] . BMC Pulm Med, 2008, 8: 25. DOI: 10.1186/1471-2466-8-25.

柯蕊, 肖雪, 和平, 等. apelin抑制肺动脉平滑肌细胞增殖的分子机制研究[J]. 中国医学创新, 2021, 18(16): 25-29. DOI: 10.3969/j.issn.1674-4985.2021.16.006.

KE R, XIAO X, HE P, et al . Molecular mechanism of apelin inhibiting proliferation of pulmonary arterial smooth muscle cells[J ] . Med Innov China, 2021, 18(16): 25-29. DOI: 10.3969/j.issn.1674-4985.2021.16.006.

CHEN M, CAI H, YU C, et al . Salidroside exerts protective effects against chronic hypoxia-induced pulmonary arterial hypertension via AMPKα1-dependent pathways[J ] . Am J Transl Res, 2016, 8(1): 12-27.

PEZZUTO B, BADAGLIACCA R, POSCIA R, et al . Circulating biomarkers in pulmonary arterial hypertension: update and future direction[J ] . J Heart Lung Transplant, 2015, 34(3): 282-305. DOI: 10.1016/j.healun.2014.12.005.

SELIMOVIC N, BERGH C H, ANDERSSON B, et al . Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension[J ] . Eur Respir J, 2009, 34(3): 662-668. DOI: 10.1183/09031936.00174908.

ZHAO Y, LV W T, PIAO H Y, et al . Role of platelet-derived growth factor-BB (PDGF-BB) in human pulmonary artery smooth muscle cell proliferation[J ] . J Recept Signal Transduct Res, 2014, 34(4): 254-260. DOI: 10.3109/10799893.2014.908915.

PERROS F, MONTANI D, DORFMVLLER P, et al . Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension[J ] . Am J Respir Crit Care Med, 2008, 178(1): 81-88. DOI:10.1164/rccm.200707-1037OC.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

人工周期下宫颈脱落细胞基因表达特征与子宫内膜容受性的关联

妊娠合并肺动脉高压产妇的围术期麻醉管理

亚硝酸钠和单硝酸异山梨酯对高肺血流肺动脉高压大鼠肺动脉压力和肺血管重塑的影响

bcl-2/bax表达在左向右分流型肺动脉高压肺血管重构中的作用